Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
Su J, Brunner L, Ates Oz E, Sacherl J, Frank G, Kerth HA, Thiele F, Wiegand M, Mogler C, Aguilar JC, Knolle PA, Collin N, Kosinska AD, Protzer U. Su J, et al. Among authors: aguilar jc. J Hepatol. 2023 Apr;78(4):717-730. doi: 10.1016/j.jhep.2022.12.013. Epub 2023 Jan 9. J Hepatol. 2023. PMID: 36634821 Free article.
Optimization of a Therapeutic Vaccine Candidate by Studying Routes, Immunization Schedules and Antigen Doses in HBsAg-positive Transgenic Mice.
Trujillo H, Blanco A, García D, Freyre F, Aguiar J, Lobaina Y, Aguilar JC. Trujillo H, et al. Among authors: aguilar jc. Euroasian J Hepatogastroenterol. 2014 Jul-Dec;4(2):70-78. doi: 10.5005/jp-journals-10018-1105. Epub 2014 Jul 28. Euroasian J Hepatogastroenterol. 2014. PMID: 29699351 Free PMC article.
How to cite this article: Trujillo H, Blanco A, Garcia D, Freyre F, Aguiar J, Lobaina Y, Aguilar JC. Optimization of a Therapeutic Vaccine Candidate by Studying Routes, Immunization Schedules and Antigen Doses in HBsAg-positive Transgenic Mice. ...
How to cite this article: Trujillo H, Blanco A, Garcia D, Freyre F, Aguiar J, Lobaina Y, Aguilar JC. Optimization of a Therape …
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study.
Yoshida O, Akbar SMF, Imai Y, Sanada T, Tsukiyama-Kohara K, Miyazaki T, Kamishita T, Miyake T, Tokumoto Y, Hikita H, Tsuge M, Shimizu M, Al Mahtab M, Aguilar JC, Guillen G, Kohara M, Hiasa Y. Yoshida O, et al. Among authors: aguilar jc. Hepatol Res. 2023 Mar;53(3):196-207. doi: 10.1111/hepr.13851. Epub 2022 Nov 18. Hepatol Res. 2023. PMID: 36399406
Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant.
Acosta-Rivero N, Poutou J, Alvarez-Lajonchere L, Guerra I, Aguilera Y, Musacchio A, Rodríguez A, Aguilar JC, Falcon V, Alvarez-Obregon JC, Soria Y, Torres D, Linares M, Pérez A, Morales-Grillo J, Dueñas-Carrera S. Acosta-Rivero N, et al. Among authors: aguilar jc. Biol Res. 2009;42(1):41-56. Epub 2009 Jun 11. Biol Res. 2009. PMID: 19621132 Free article.
71 results